Dhaka: Bangladesh’s Beyxco Pharmaceutics Ltd will start selling generic version of Merck & Co’s Antiviral Pill for Covid-19 after the approval of local regulations, he said on Tuesday.
The announcement marked the launch of the first Merck bioterapeutic tablet and Ridgeback in the world, Molnupiravir, which has been mentioned as a potential beating game in the fight against Coronavirus.
Molnupiravir received his first global regulation approval, in England last week.
Still being reviewed in the United States and Europe.
Birxco will soon start selling Generic Molnupiravir, a cheaper version of Merck branded, in Bangladesh, because it accepts the authorization of emergency use for the treatment of the Directorate General of State Narcotics, he said in a statement.
Exports will depend on regulatory approval globally, he added.
Merck did not immediately respond to a request for a comment.
US drugs have signed a license agreement with at least eight Indian drug makers for Molnupiravir, aiming to change the South Asian countries into manufacturing centers to supply low and medium-sized income countries.
These include the Laboratory of Dr.
Reddy, Cipla, Sun Pharma, Torrent Pharmaceuticals, Emcure Pharmaceuticals and hetero, among others.
Birxco said it did not expect generic molnupiravir sales to increase revenue significantly, given the level of Covid-19 infection which is currently low in Bangladesh, which is neighboring India.
The shares registered in London rose 6.2% at 107.25 pence at 0825 GMT.
Birxco Bangladesh to sell generic version of Merck Covid-19 Pill
